AU2001229491A1 - Cyclic peptides as potent and selective melanocortin-4 receptor antagonists - Google Patents

Cyclic peptides as potent and selective melanocortin-4 receptor antagonists

Info

Publication number
AU2001229491A1
AU2001229491A1 AU2001229491A AU2949101A AU2001229491A1 AU 2001229491 A1 AU2001229491 A1 AU 2001229491A1 AU 2001229491 A AU2001229491 A AU 2001229491A AU 2949101 A AU2949101 A AU 2949101A AU 2001229491 A1 AU2001229491 A1 AU 2001229491A1
Authority
AU
Australia
Prior art keywords
potent
receptor antagonists
cyclic peptides
selective melanocortin
melanocortin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001229491A
Inventor
Maria A. Bednarek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2001229491A1 publication Critical patent/AU2001229491A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001229491A 2000-01-18 2001-01-16 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists Abandoned AU2001229491A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17650900P 2000-01-18 2000-01-18
US60176509 2000-01-18
PCT/US2001/001297 WO2001052880A1 (en) 2000-01-18 2001-01-16 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists

Publications (1)

Publication Number Publication Date
AU2001229491A1 true AU2001229491A1 (en) 2001-07-31

Family

ID=22644637

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001229491A Abandoned AU2001229491A1 (en) 2000-01-18 2001-01-16 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists

Country Status (6)

Country Link
US (1) US6693165B2 (en)
EP (1) EP1251865A1 (en)
JP (1) JP2003534240A (en)
AU (1) AU2001229491A1 (en)
CA (1) CA2396307A1 (en)
WO (1) WO2001052880A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US20030113263A1 (en) * 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
WO2003013571A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7130911B2 (en) * 2002-02-11 2006-10-31 Intel Corporation Method for monitoring unauthorized access to data stored in memory buffers
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2368579A1 (en) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
WO2005103715A2 (en) * 2004-04-27 2005-11-03 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
US7754691B1 (en) 2005-07-07 2010-07-13 Palatin Technologies, Inc. Linear melanocortin receptor-specific peptides for cachexia
EP1968995A1 (en) * 2005-12-30 2008-09-17 F. Hoffmann-la Roche AG Methods for the synthesis of arginine-containing peptides
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2300036B1 (en) 2008-06-09 2017-04-05 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
US20090305960A1 (en) * 2008-06-09 2009-12-10 Palatin Technologies, Inc Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
MX2011004258A (en) 2008-10-22 2011-06-01 Merck Sharp & Dohme Novel cyclic benzimidazole derivatives useful anti-diabetic agents.
CN102271509A (en) 2008-10-31 2011-12-07 默沙东公司 Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX2011013117A (en) 2009-06-08 2012-05-23 Palatin Technologies Inc Melanocortin receptor-specific peptides.
UY32690A (en) 2009-06-08 2011-01-31 Astrazeneca Ab SPECIFIC PEPTIDES FOR MELANOCORTIN RECEPTORS
EP2440572B1 (en) * 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
EA201290295A1 (en) 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. SPECIFIC TO MELANOCORTIN-1 RECEPTOR LINEAR PEPTIDES
CA2781402C (en) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MY159058A (en) 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
KR102272746B1 (en) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
PL422093A1 (en) * 2017-07-03 2019-01-14 Uniwersytet Warszawski New hybrid peptidomimetics for applications in neuropathic pain
US20210161958A1 (en) * 2018-04-19 2021-06-03 The Trustees Of The University Of Pennsylvania Compositions and methods for treating melanoma with a chimeric antigen receptor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649191A (en) 1984-05-10 1987-03-10 Gibson-Stephens Neuropharmaceuticals, Inc. Conformationally constrained alpha-melanotropin analogs with specific central nervous system activity
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
DE69738353T2 (en) 1996-07-12 2009-09-24 Immunomedics, Inc. RADIOMETALL-BINDING PEPTIDE ANALOG
EP0946595A2 (en) 1996-12-17 1999-10-06 Quadrant Holdings Cambridge Limited Melanocortins
SE9700620D0 (en) 1997-02-21 1997-02-21 Wapharm Ab Cyclic peptides with selectivity for MSH receptor subtypes
US6228840B1 (en) 1998-02-27 2001-05-08 Edward T. Wei Melanocortin receptor antagonists and modulations of melanocortin receptor activity
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
TR200102765T2 (en) * 1999-03-29 2002-05-21 The Procter & Gamble Company Melanocortin receptor ligands

Also Published As

Publication number Publication date
JP2003534240A (en) 2003-11-18
US6693165B2 (en) 2004-02-17
EP1251865A1 (en) 2002-10-30
WO2001052880A1 (en) 2001-07-26
CA2396307A1 (en) 2001-07-26
US20020016291A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
AU2001229491A1 (en) Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
SI1315750T1 (en) Cyclic peptides having melanocortin-4 receptor agonist activity
AU2001250407A1 (en) Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity
IL156304A0 (en) Cxcr3 antagonists
AU6690001A (en) Thrombin receptor antagonists
WO2003006620A3 (en) Linear and cyclic melanocortin receptor-specific peptides
IL153360A0 (en) Chemically-modified peptides, compositions, and methods of production and use
AU2002341123A1 (en) N-aroyl cyclic amine derivatives as orexin receptor antagonists
AU2002352447A1 (en) N-aroyl cyclic amine derivatives as orexin receptor antagonists
AU2001269876A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
SG99324A1 (en) Microporous soundproofing material
AU2001264657A1 (en) Crf receptor antagonists
GB0130261D0 (en) Lactams as tachykinin antagonists
AU2001290772A1 (en) Alpha v integrin receptor antagonists
IL142045A0 (en) Naphthalenecarboxamides as tachykinin receptor antagonists
EP1296958A4 (en) Iminopyrimidine nmda nr2b receptor antagonists
AU2001240021A1 (en) Diazafluorenone il-8 receptor antagonists
EP1178802A4 (en) Cyclic amidines useful as nmda nr2b antagonists
AU2001278626A1 (en) Tetrahydropyran derivatives as nk-1 receptor antagonists
AU2002216079A1 (en) Bombesin receptor antagonists
AU2002239506A1 (en) Urotensin-ii receptor antagonists
AU2002217095A1 (en) Bombesin receptor antagonists
PL357875A1 (en) Cyclic hexapeptide derivatives
AU2002352388A1 (en) N-aroyl cyclic amine derivatives and their use as orxin receptor antagonist
AU6127498A (en) Msh-receptor subtype selective cyclic peptides